SAFETY DATA SHEET

Mometasone Dry Powder Inhaler Formulation

Version: 2.8  Revision Date: 09/13/2019  SDS Number: 437306-00010  Date of last issue: 24.04.2019
Date of first issue: 28.01.2016

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Mometasone Dry Powder Inhaler Formulation

Manufacturer or supplier’s details
Company: MSD
Address: 26 Talavera Road, Talavera Corp Centre, Macquarie Park New South Wales, 2113 Australia
Telephone: (61)-02-8988-8000
Emergency telephone number: (61)-02-8988-8000
E-mail address: EHSDATASTEWARD@msd.com
Telefax: 908-735-1496

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification
Reproductive toxicity: Category 1B
Specific target organ toxicity - repeated exposure (Inhalation): Category 2 (Immune system, Liver, Kidney, Skin)

GHS label elements
Hazard pictograms:
Signal word: Danger
Hazard statements: H360Df May damage the unborn child. Suspected of damaging fertility. H373 May cause damage to organs (Immune system, Liver, Kidney, Skin) through prolonged or repeated exposure if inhaled.

Precautionary statements:
Prevention:
P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe dust. P281 Use personal protective equipment as required.
Response:
P308 + P313 IF exposed or concerned: Get medical advice/attention.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/container to an approved waste disposal plant.

Other hazards which do not result in classification
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mometasone</td>
<td>83919-23-7</td>
<td>&gt;= 10 -&lt; 30</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May damage the unborn child. Suspected of damaging fertility.
May cause damage to organs through prolonged or repeated exposure if inhaled.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment.
SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media: Water spray
                               Alcohol-resistant foam
                               Carbon dioxide (CO2)
                               Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
                               Chlorine compounds

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Hazchem Code: 2Z

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions: Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spills cannot be contained.

Methods and materials for containment and cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
SECTION 7. HANDLING AND STORAGE

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling: Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents.

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mometasone</td>
<td>83919-23-7</td>
<td>TWA</td>
<td>1 µg/m³ (OEB 4)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>10 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Further information: Skin

Engineering measures: Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying
from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies.

**Personal protective equipment**

**Respiratory protection**: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

- **Filter type**: Particulates type

**Hand protection**

- **Material**: Chemical-resistant gloves

**Remarks**: Consider double gloving.

**Eye protection**

- **Material**: Chemical-resistant goggles. Wear safety glasses with side shields or goggles.
- If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection**

- **Material**: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>powder</td>
</tr>
<tr>
<td>Colour</td>
<td>white</td>
</tr>
<tr>
<td>Odour</td>
<td>No data available</td>
</tr>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>May form explosive dust-air mixture during processing, handling or other means.</td>
</tr>
</tbody>
</table>
### SAFETY DATA SHEET

**Mometasone Dry Powder Inhaler Formulation**

---

**Version** 2.8  
**Revision Date:** 09/13/2019  
**SDS Number:** 437306-00010  
**Date of last issue:** 24.04.2019  
**Date of first issue:** 28.01.2016

<table>
<thead>
<tr>
<th>Property</th>
<th>Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapour pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative vapour density</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td>Water solubility</td>
</tr>
<tr>
<td></td>
<td>No data available</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>No data available</td>
</tr>
<tr>
<td>Auto-ignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td>Viscosity, kinematic</td>
</tr>
<tr>
<td></td>
<td>No data available</td>
</tr>
<tr>
<td>Explosive properties</td>
<td>Not explosive</td>
</tr>
<tr>
<td>Oxidizing properties</td>
<td>The substance or mixture is not classified as oxidizing.</td>
</tr>
<tr>
<td>Molecular weight</td>
<td>No data available</td>
</tr>
<tr>
<td>Particle size</td>
<td>No data available</td>
</tr>
</tbody>
</table>

---

**SECTION 10. STABILITY AND REACTIVITY**

**Reactivity** : Not classified as a reactivity hazard.

**Chemical stability** : Stable under normal conditions.

**Possibility of hazardous reactions** : May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

**Conditions to avoid** : Heat, flames and sparks. Avoid dust formation.

**Incompatible materials** : Oxidizing agents

**Hazardous decomposition products** : No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION**

**Exposure routes** : Inhalation
Skin contact
Ingestion
Eye contact

**Acute toxicity**
Not classified based on available information.

**Components:**

**Mometasone:**

**Acute oral toxicity**
- LD50 (Rat): > 2,000 mg/kg
- LD50 (Mouse): > 2,000 mg/kg

**Acute inhalation toxicity**
- LC50 (Rat): > 3.3 mg/l
  - Exposure time: 4 h
  - Test atmosphere: dust/mist
  - Remarks: No mortality observed at this dose.
- LC50 (Mouse): > 3.2 mg/l
  - Exposure time: 4 h
  - Test atmosphere: dust/mist

**Acute toxicity (other routes of administration)**
- LD50 (Rat): 300 mg/kg
  - Application Route: Subcutaneous
  - Symptoms: Breathing difficulties

**Skin corrosion/irritation**
Not classified based on available information.

**Components:**

**Mometasone:**

**Species**
- Rabbit

**Result**
- No skin irritation

**Serious eye damage/eye irritation**
Not classified based on available information.

**Components:**

**Mometasone:**

**Species**
- Rabbit

**Result**
- No eye irritation

**Respiratory or skin sensitisation**

**Skin sensitisation**
Not classified based on available information.

**Respiratory sensitisation**
Not classified based on available information.
Components:

Mometasone:

Test Type : Maximisation Test
Exposure routes : Dermal
Species : Guinea pig
Assessment : Does not cause skin sensitisation.
Result : negative
Remarks : The results of a test on guinea pigs showed this substance to be a weak skin sensitiser.

Chronic toxicity

Germ cell mutagenicity
Not classified based on available information.

Components:

Mometasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster lung cells
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: positive

Test Type: Mouse Lymphoma
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Test Type: Chromosomal aberration
Species: Rat
Cell type: Bone marrow
Result: negative

Test Type: unscheduled DNA synthesis assay
Species: Rat
Cell type: Liver cells
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity
Not classified based on available information.
Components:

Mometasone:

<table>
<thead>
<tr>
<th>Species</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Dose</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Inhalation</td>
<td>2 Years</td>
<td>0.067 mg/kg body weight</td>
<td>negative</td>
</tr>
<tr>
<td>Mouse</td>
<td>Inhalation</td>
<td>19 Months</td>
<td>0.160 mg/kg body weight</td>
<td>negative</td>
</tr>
</tbody>
</table>

Reproductive toxicity
May damage the unborn child. Suspected of damaging fertility.

Components:

Mometasone:

Effects on fertility:

<table>
<thead>
<tr>
<th>Test Type: Fertility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
</tr>
<tr>
<td>Application Route: Subcutaneous</td>
</tr>
<tr>
<td>Fertility: NOAEL: 0.015 mg/kg body weight</td>
</tr>
<tr>
<td>Symptoms: Reduced embryonic survival, Reduced foetal weight</td>
</tr>
<tr>
<td>Result: No effects on fertility, Effect on reproduction capacity</td>
</tr>
</tbody>
</table>

Effects on foetal development:

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Mouse</td>
</tr>
<tr>
<td>Application Route: Subcutaneous</td>
</tr>
<tr>
<td>Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight</td>
</tr>
<tr>
<td>Result: Embryotoxic effects, Teratogenicity and developmental toxicity</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
</tr>
<tr>
<td>Application Route: Dermal</td>
</tr>
<tr>
<td>Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight</td>
</tr>
<tr>
<td>Result: Embryo-foetal toxicity</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rabbit</td>
</tr>
<tr>
<td>Application Route: Dermal</td>
</tr>
<tr>
<td>Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight</td>
</tr>
<tr>
<td>Result: Embryo-foetal toxicity, Malformations were observed.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
</tr>
<tr>
<td>Application Route: Subcutaneous</td>
</tr>
<tr>
<td>Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight</td>
</tr>
<tr>
<td>Result: Effects on newborn</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
</tr>
<tr>
<td>Application Route: Subcutaneous</td>
</tr>
<tr>
<td>Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight</td>
</tr>
<tr>
<td>Result: Effects on newborn</td>
</tr>
</tbody>
</table>
Species: Rabbit
Application Route: Oral
Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight
Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - Assessment
: Clear evidence of adverse effects on development, based on animal experiments. Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT - single exposure
Not classified based on available information.

Components:
Mometasone:
Remarks : Based on available data, the classification criteria are not met.

STOT - repeated exposure
May cause damage to organs (Immune system, Liver, Kidney, Skin) through prolonged or repeated exposure if inhaled.

Components:
Mometasone:
Exposure routes : inhalation (dust/mist/fume)
Target Organs : Immune system, Liver, Kidney, Skin
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:
Mometasone:
Species : Rat
NOAEL : 0.005 mg/kg
LOAEL : 0.3 mg/kg
Application Route : Oral
Exposure time : 30 d
Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland
Species : Dog
LOAEL : 0.5 mg/kg
Application Route : Oral
Exposure time : 30 d
Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland
Species : Rat
NOAEL : 0.00013 mg/l
Application Route : inhalation (dust/mist/fume)
Exposure time : 90 d
Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland
Species: Dog
NOAEL: 0.0005 mg/l
Application Route: inhalation (dust/mist/fume)
Exposure time: 90 d
Target Organs: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

**Aspiration toxicity**
Not classified based on available information.

**Components:**
Mometasone: Not applicable

**Experience with human exposure**

**Components:**
Mometasone:
Inhalation: Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion
Skin contact: Symptoms: Dermatitis, Itching

**Further information**

**Components:**
Mometasone:
Remarks: Dermal absorption possible

---

**SECTION 12. ECOLOGICAL INFORMATION**

**Ecotoxicity**

**Components:**
Mometasone:
Toxicity to fish: LC50 (Menidia beryllina (Silverside)): 0.11 mg/l
   Exposure time: 96 h
   Remarks: No toxicity at the limit of solubility

   LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l
   Exposure time: 7 d
   Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 5 mg/l
   Exposure time: 48 h
   Method: OECD Test Guideline 202
   Remarks: No toxicity at the limit of solubility

   EC50 (Americamysis): > 5 mg/l
   Exposure time: 96 h
SAFETY DATA SHEET
Mometasone Dry Powder Inhaler Formulation

Method: US-EPA OPPTS 850.1035
Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity): NOEC (Pimephales promelas (fathead minnow)): 0.00014 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC (Daphnia magna (Water flea)): 0.34 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms: EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility

NOEC: 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility

Persistence and degradability

Components:

Mometasone:
Biodegradability: Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Stability in water: Hydrolysis: 50 % (12 d)
Method: OECD Test Guideline 111

Bioaccumulative potential

Components:

Mometasone:
Bioaccumulation: Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 107.1
Method: OECD Test Guideline 305

Partition coefficient: n- log Pow: 4.68
octanol/water

**Mobility in soil**

**Components:**

**Mometasone:**
Distribution among environmental compartments: \( \text{log Koc: 4.02} \)

**Other adverse effects**
No data available

### SECTION 13. DISPOSAL CONSIDERATIONS

**Disposal methods**
- Waste from residues: Dispose of in accordance with local regulations.
- Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

### SECTION 14. TRANSPORT INFORMATION

**International Regulations**

**UNRTDG**
- UN number: UN 3077
- Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
- Class: 9
- Packing group: III
- Labels: 9

**IATA-DGR**
- UN/ID No.: UN 3077
- Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Mometasone)
- Class: 9
- Packing group: III
- Labels: Miscellaneous
- Packing instruction (cargo aircraft): 956
- Packing instruction (passenger aircraft): 956
- Environmentally hazardous: yes

**IMDG-Code**
- UN number: UN 3077
- Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
- Class: 9
- Packing group: III
- Labels: 9
- EmS Code: F-A, S-F
Marine pollutant: yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**
Not applicable for product as supplied.

### National Regulations

**ADG**
- UN number: UN 3077
- Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
- Class: 9
- Packing group: III
- Labels: 9
- Hazchem Code: 2Z

### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

### SECTION 15. REGULATORY INFORMATION

**Safety, health and environmental regulations/legislation specific for the substance or mixture**

Prohibition/Licensing Requirements: There is no applicable prohibition or notification/licensing requirements, including for carcinogens under Commonwealth, State or Territory legislation.

**The components of this product are reported in the following inventories:**
- AICS: not determined
- DSL: not determined
- IECSC: not determined

### SECTION 16. OTHER INFORMATION

**Further information**
- Revision Date: 09/13/2019
- Date format: dd.mm.yyyy
SAFETY DATA SHEET

Mometasone Dry Powder Inhaler Formulation

Version 2.8  Revision Date: 09/13/2019  SDS Number: 437306-00010  Date of last issue: 24.04.2019  Date of first issue: 28.01.2016

Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

AU / EN